Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy

Phase 2

Completed

• Conditions: Carcinoma Renal Cells
• Interventions: Drug: Sunitinib

• Registration Number: NCT00663559
• Lead Sponsor: Spanish Oncology Genito-Urinary Group

Brief Summary

The purpose of this trial is to determinate the efficacy of Sunitinib in patients with renal cells carcinoma metastasic or locally avanced in patints not candidates to inicial curative nefrectomy.

Detailed Description

Study phase II in with one arm in patients with renal cells carcinoma.

Study Timeline

• Status Verified: 2007-11
• Study Start: 2008-02
• Study First Submitted: 2008-04-21
• Study First Submitted QC: 2008-04-21
• Study First Posted: 2008-04-22
• Primary Completion: 2009-08
• Study Completion: 2010-02
• Last Update Submitted: 2014-12-17
• Last Update Posted: 2014-12-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

• Patients must give their written informed consent before any procedure related to the study is performed.

• Patients with renal clear cell carcinoma metastatic or locally advanced, histologically or cytologically documented.The patients with metastasic disease must be not condidated to curative nefrectomy as investigator criteria.

• Assessable or measurable disease according to RECIST criteria. The lesions previosly radiated is not considered as target.

• Ages equal or superior to 18 years old.

• ECOG ≤ 1

• Patients with a life expectancy superior to 12 weeks.

• Patients with adequate organic function, according to the following criteria:

  1. . Medular reserve: Neutrophils absolute count≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Haemoglobin ≥ 9g/dl
  2. . Hepatic function: Total bilirubin < 1.5 times the superior limit of normality ALT and AST < 2.5 times the superior limit of normality (< 5 times the superior limit of normality in case of liver failure due to cancer)
  3. . Seric Albumin ≥ 1.5 times the superior limit of normality
  4. . Renal Function: Cleary creatinine > 30ml/min
  5. . FEVI > LIN according to ECO or MUGA

• Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions while on study

Exclusion Criteria

• Pregnant or breastfeeding women. Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication. Both men and women included in the study must use an adequate contraceptive method.
• Patients that have received sistemic treatment previous to metastasic disease.
• Previous nefrectomy.
• Mayor Surgery, radiotherapy or sistemic therapy received in the last 3 weeks previous to the inclusion of the patient in the study, except paliative radiotherapy upper no target lesions.
• Radiotherapy upper > 25% bone marrow.
• Patients that are participating in any clinical trial.
• Patients with a primary cancer diagnosis in thast 3 years, except superficial basaliomas, superficial escamous carcinoma or in situ cervix carcinoma with aducuate treatment.
• Following events in the last 12 months previous to begin the treatment: myocardial infarction, unstable o severe angina, coronary/periferic place of arterial by-pass, congestive cardiac insufficiency, brain-vascular accident included transitory ischemia or lung embolism.
• Arterial uncontrolled hypertension nor controlated with drugs ( >150/100 mmHg despite adequate medical treatment).
• Cardiac arrhythmia with grade NCI CTCAE ≥2, auricular fibrillation all grade and/or QTc interval> 450mseg in men and > 470 mseg in women.
• Actually treatment with therapeutic dose with acenocumarol (except low dose for deep venous thrombosis).
• Patients that present previously known positive serology for HIV.
• Abuse of substances, clinical conditions, psychological or social, that may interfere with the patient's participation in the study or with the evaluation of the study's results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Sunitinib	This study has only one arm with Sunitinib

Primary Outcome Measures

Name	Time	Method
Progression-free survival	every 12 weeks

Secondary Outcome Measures

Name	Time	Method
Global survival	At last contact date or death date
Response global	Every 12 weeks
Duration of response	Every 12 weeks
Security and tolerability of Sunitinib	Every 4 weeks

Trial Locations

Locations (7)

Hospital Parc Taulí; 🇪🇸 Sabadell, Barcelona, Spain

Hospital lozano Blesa; 🇪🇸 Zaragoza, Spain

Hospital CLINIC; 🇪🇸 Barcelona, Spain

Hospital Central de Asturias; 🇪🇸 Oviedo, Asturias, Spain

Hospital de Jaén; 🇪🇸 Jaén, Spain

Hospital Reina Sofía; 🇪🇸 Córdoba, Spain

Hospital Clínico San Carlos; 🇪🇸 Madrid, Spain